ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Phosphorylated STYK1 Promotes Gemcitabine Resistance via Autophagy-Mediated Cancer Stemness in Pancreatic Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with gemcitabine resistance remaining a major clinical challenge. Although cancer stemness and autophagy have both been implicated in PDAC chemoresistance, the mechanism by which their crosstalk governs gemcitabine resistance remains poorly understood. Here, we identify serine/threonine/tyrosine kinase 1 (STYK1) as a critical mediator of gemcitabine resistance through autophagy- dependent maintenance of pancreatic cancer stemness. Mechanistically, gemcitabine activates AMP-activated protein kinase (AMPK), which contributes to the enhancement of STYK1-mediated autophagic flux, thereby promoting stemness-associated chemoresistance. Furthermore, AMPK phosphorylates STYK1 at residues Ser91 and Ser304, thereby further potentiating STYK1-mediated autophagy and cancer stemness. Importantly, we developed SAIDP5, a therapeutic peptide disrupting STYK1-AMPK binding, which synergizes with gemcitabine to attenuate chemoresistance. This study reveals that gemcitabine-induced AMPK activation amplifies STYK1-driven autophagy and cancer stemness, thereby contributing to gemcitabine resistance, and highlights SAIDP5 as a promising peptide-based strategy to improve gemcitabine efficacy in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.